Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of fevipiprant added to standard asthma therapy
MOH_2017-06-20_000471Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fevipiprant in asthma (3 arms), sponsored by Novartis. Primary endpoint: Long-term safety of fevipiprant. Started Jun 2017; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2017-06-20_000471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-20_000471.